Cargando…

A cross-sectional study from Qatar on the effect of influenza vaccination on the severity of COVID-19

To assess and compare the severity of corona virus disease 2019 (COVID-19) infection in patients with and without a history of influenza vaccination. In this cross-sectional study descriptive statistics were used to analyze COVID-19-related parameters, including demographics, comorbidities, and seve...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Merlin, Ismail, Shanima, Hameed, Mansoor, Kazi, Sabeeha Sayed Tarique, Chandra, Prem, Raza, Tasleem, Paul, Theresa, Sattar, Hisham Abdul, Suliman, Aasir M., Mohamed, Sara Saeed Ibrahim, Ibrahim, Ezzedin A. Salam, Subahi, Eihab Abd Alla Abd Elrahim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508454/
https://www.ncbi.nlm.nih.gov/pubmed/37713897
http://dx.doi.org/10.1097/MD.0000000000035107
Descripción
Sumario:To assess and compare the severity of corona virus disease 2019 (COVID-19) infection in patients with and without a history of influenza vaccination. In this cross-sectional study descriptive statistics were used to analyze COVID-19-related parameters, including demographics, comorbidities, and severity. Normally distributed data with mean, standard deviation, and 95% confidence interval (CI) were reported, while non-normally distributed data was presented with median and inter-quartile range. Categorical data was summarized using frequencies and percentages. Associations were assessed using Pearson Chi-square, Fisher Exact, t test, or Mann–Whitney U test. Univariate and multivariate logistic regression methods were used to evaluate the relationship between disease severity, clinical outcomes, influenza vaccination status, and other predictors. Significance was considered for p values < 0.05. Statistical analyses were done using SPSS V.27.0 (IBM Corp) and Epi Info (CDC) software. Between March 2020 and December 2020 before the availability of COVID-19 vaccination, 148,215 severe acute respiratory syndrome corona virus 2 positive patients were studied, with 3519 vaccinated against influenza, and 144,696 unvaccinated. After random sampling at 1:2 ratio, the final analysis included 3234 vaccinated and 5640 unvaccinated patients. The majority (95.4%) had mild or asymptomatic COVID-19, while 4.6% had severe or critical cases as defined by World Health Organization severity grading. Multivariate logistic regression analysis revealed that the vaccinated group had significantly less severe (adjusted odds ratio [OR] 0.683; 95% CI 0.513–0.911, P = .009) and critical (adjusted OR 0.345; 95% CI 0.145–0.822, P = .016) COVID-19 and were less likely to require oxygen therapy (adjusted OR 0.696; 95% CI 0.531–0.912, P = .009) after adjusting for confounders like age, gender and comorbidities. No significant differences in Intensive care unit admissions (adjusted OR 0.686; 95% CI 0.425–1.11, P = .122), mechanical ventilation (adjusted OR 0.631; 95% CI 0.308–1.295, P = .209) and mortality (adjusted OR 1.105; 95% CI 0.348–3.503, P = .866) were noted between the 2 groups. Influenza vaccination may significantly reduce the severity of COVID-19 but has no significant effect on intensive care unit admissions, mechanical ventilation and all- cause mortality.